These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29606053)

  • 1. High-grade meningiomas: biology and implications.
    Bi WL; Prabhu VC; Dunn IF
    Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
    Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
    Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
    Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
    Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
    Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
    Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study.
    Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA
    J Neurosurg; 2024 Jul; 141(1):72-78. PubMed ID: 38277657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
    Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1.
    Sievers P; Sill M; Blume C; Tauziede-Espariat A; Schrimpf D; Stichel D; Reuss DE; Dogan H; Hartmann C; Mawrin C; Hasselblatt M; Stummer W; Schick U; Hench J; Frank S; Ketter R; Schweizer L; Schittenhelm J; Puget S; Brandner S; Jaunmuktane Z; Küsters B; Abdullaev Z; Pekmezci M; Snuderl M; Ratliff M; Herold-Mende C; Unterberg A; Aldape K; Ellison DW; Wesseling P; Reifenberger G; Wick W; Perry A; Varlet P; Pfister SM; Jones DTW; von Deimling A; Sahm F;
    Acta Neuropathol; 2021 Feb; 141(2):281-290. PubMed ID: 33319313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline and somatic mutations in meningiomas.
    Smith MJ
    Cancer Genet; 2015 Apr; 208(4):107-14. PubMed ID: 25857641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic analysis of spinal meningiomas: correlation with histopathological grade.
    Driver J; Santagata S; Bi WL; Chi JH
    J Neurosurg Spine; 2023 Dec; 39(6):729-733. PubMed ID: 37728381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
    Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
    Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWI/SNF chromatin remodeling complex alterations in meningioma.
    Gill CM; Loewenstern J; Rutland JW; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Shrivastava RK
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3431-3440. PubMed ID: 33715086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
    Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
    Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO grade III meningioma: De novo tumors show improved progression free survival as compared to secondary progressive tumors.
    Ruzevick J; Gibson A; Tatman P; Emerson S; Ferreira M
    J Clin Neurosci; 2021 Sep; 91():105-109. PubMed ID: 34373013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
    Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
    Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMARCB1 mutations are not a common cause of multiple meningiomas.
    Hadfield KD; Smith MJ; Trump D; Newman WG; Evans DG
    J Med Genet; 2010 Aug; 47(8):567-8. PubMed ID: 20472658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules.
    Torres-Martín M; Kusak ME; Isla A; Burbano RR; Pinto GR; Melendez B; Castresana JS; Rey JA
    Cancer Genet; 2015 Jun; 208(6):327-32. PubMed ID: 25981829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.